CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed today that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.

As a consequence, the company is in contact with especially CEPI and many other organizations and authorities worldwide, however abstains from commenting on speculations and rejects allegations about offers for acquisition of the company or its technology.

Based on its inherent mode of action, CureVac sees mRNA as one of the most potent molecules to provide fast and efficient solutions in outbreak scenarios, such like the Coronavirus. With inhouse expertise of over two decades and the company’s deep scientific understanding CureVac is leveraging its potent vaccine platform to focus on developing a potent, efficacious and safe and fast to produce vaccine against Covid-19.

CureVac recently announced successful vaccination results in its Rabies program fully protecting humans with two doses of only 1 microgram (1 millionth of a gram). These results are encouraging when thinking of supplying populations and people worldwide in a pandemic scenario.